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Background:	Simultaneous	 cardiac	perfusion	studies	are	an	 increasing	trend	 in	PET-MR	 imaging.	 During	 dynamic	 PET	 imaging,	 the	 introduction	 of	 gadolinium-based	MR	contrast	agents	(GBCA)	at	high	concentrations	during	a	dual	injection	of	GBCA	and	PET	radiotracer	may	cause	increased	attenuation	effects	of	the	PET	signal,	and	thus	errors	in	 quantification	 of	 PET	 images.	 	 We	 thus	 aimed	 to	 calculate	 the	 change	 in	 linear	attenuation	 coefficient	 (LAC)	 of	 a	 mixture	 of	 PET	 radiotracer	 and	 increasing	concentrations	of	GBCA	in	solution	and	furthermore	to	investigate	if	this	change	in	LAC	produced	 a	 measurable	 effect	 on	 the	 image-based	 PET	 activity	 concentration	 when	attenuation	corrected	by	3	different	AC	strategies.		
Findings:	 We	 performed	 simultaneous	 PET-MR	 imaging	 of	 a	 phantom	 in	 a	 static	scenario	 using	 a	 fixed	 activity	 of	 40	 MBq	 [18F]-NaF,	 water	 and	 increasing	 GBCA	concentration	 from	 0	 to	 66	 mM	 (based	 on	 an	 assumed	 maximum	 possible	concentration	of	GBCA	in	the	left	ventricle	in	a	clinical	study).	This	simulated	a	range	of	clinical	concentrations	of	GBCA.	We	investigated	2	methods	to	calculate	the	LAC	of	the	solution	mixture	at	511	keV:	1)	a	mathematical	mixture	rule	and	2)	CT	imaging	of	each	concentration	 step	 and	 subsequent	 conversion	 to	 LAC	 at	 511	 keV.	 This	 comparison	showed	 that	 the	 ranges	 of	 LAC	 produced	 by	 both	 methods	 are	 equivalent	 with	 an	increase	in	LAC	of	the	mixed	solution	of	approximately	2%	over	the	range	of	0-66	mM.	We	then	employed	3	different	attenuation	correction	methods	to	the	PET	data:	1)	each	PET	 scan	 at	 a	 specific	mM	 concentration	 of	 GBCA	 corrected	 by	 its	 corresponding	 CT	scan,	 2)	 each	 PET	 scan	 corrected	 by	 a	 CT	 scan	 with	 no	 GBCA	 present	 (i.e.	 at	 0	 mM	GBCA)	 and	 3)	 a	 manually	 generated	 attenuation	 map,	 whereby	 all	 CT	 voxels	 in	 the	phantom	at	0	mM	were	replaced	by	LAC=0.1	cm-1.	All	attenuation	correction	methods	(1-3)	were	accurate	to	the	true	measured	activity	concentration	within	5%,	and	there	
  
were	 no	 trends	 in	 image-based	 activity	 concentrations	 upon	 increasing	 the	 GBCA	concentration	of	the	solution.		
Conclusion	 The	 presence	 of	 high	 GBCA	 concentration	 (representing	 a	 worst	 case	scenario	 in	 dynamic	 cardiac	 studies)	 in	 solution	 with	 PET	 radiotracer	 produces	 a	minimal	effect	on	attenuation-corrected	PET	quantification.		
	
Keywords:	PET/MR;	attenuation	correction;	cardiac	PET		
Introduction Gadolinium	 based	 contrast	 agents	 (GBCA)	 represent	 the	 most	 common	 types	 of	Magnetic	 Resonance	 contrast	 agents,	 used	 primarily	 as	 a	 T1	 contrast	 agent.	 GBCA	consist	of	 transitional	 (i.e.	 heavy)	metal	Gd	 ions	bound	by	 chelating	agents	 to	 form	a	stable	 complex	 of	 relatively	 low	 toxicity	 (1).	 Many	 GBCA	 have	 different	 molecular	structures	yet	similar	pharmacokinetic	properties,	and	therefor	few	differences	can	be	discerned	in	clinical	practice	(2).	Paramagnetic	ions	such	as	Gd3+	in	GBCA	dissolved	in	an	aqueous	solution	act	as	microscopic	magnets	in	the	local	environment	causing	water	protons	 to	 “feel”	 a	 large	 magnetic	 moment	 and	 thus	 a	 local	 change	 in	 the	 average	relaxation	time.	They	are	most	commonly	employed	due	to	a	predominant	shortening	of	T1	relaxation	time,	which	results	 in	an	increased	signal	 intensity	on	a	T1-weighted	image	(known	as	positive	enhancement).			The	 use	 of	 simultaneous	 PET-MR	 (Positron	 Emission	 Tomography	 –	 Magnetic	Resonance)	in	cardiology	opens	up	the	potential	for	the	simultaneous	injection	of	a	PET	perfusion	 tracer	 (such	 as	 [15O]-H2O,	 [13N]-NH3,	 or	 [82Rb]-Cl)	 with	 GBCA	 for	 parallel	myocardial	 perfusion	 quantification	 using	 both	 methodologies.	 Also	 as	 cardiac	 MR	
  
imaging	is	prone	to	scanner-dependent	calibration	curves	and	saturation	effects	(3,	4),	this	quantification	methodology	could	also	allow	direct	comparison	between	calculated	PET	and	MR	perfusion	variables	and	quantification	techniques	(5).			Previous	 investigations	of	 the	 effect	 of	GBCA	 in	 clinical	PET-MR	 imaging	have	 shown	that	MR-based	 attenuation	maps	 acquired	 via	 a	 2-point	 VIBE-based	DIXON	 sequence	(whereby	an	automated	segmentation	algorithm	provides	4	different	tissue	classes,	fat,	soft	tissue,	lung	and	air)	may	be	affected	only	by	orally-administered	iron-oxide	based	contrast	agent,	and	that	neither	 intra-venous	injections	nor	orally	administered	GBCA	significantly	 affect	 the	 attenuation	 of	 the	 PET	 emission	 data	 (6).	 This	 group’s	 work	looked	 at	 clinically	 relevant	 concentrations	 of	 GBCA	 for	 static	 whole-body	 imaging,	determining	 a	 worst-case	 scenario	 for	 the	 concentration	 in	 blood.	 However,	 not	 yet	investigated	 are	 the	 technical	 considerations	 for	 a	 dynamic	 simultaneous	 PET-MR	acquisition,	 such	as	 those	 required	 for	 calculation	of	an	 image-derived	 input	 function	and	myocardial	uptake	curves	in	PET	cardiology	studies.			In	 this	work,	we	aimed	to	assess	 the	effects	of	high	concentrations	of	GBCA	firstly	on	the	change	in	linear	attenuation	coefficient	(LAC	–	the	fraction	of	photons	absorbed	per	unit	thickness	of	the	material)	of	a	solution	of	increasing	GBCA	concentration	and	PET	radiotracer,	and	secondly	on	PET	image-based	activity	concentration.	We	employed	CT	imaging	and	a	mathematical	model	to	provide	measurements	of	the	LAC	at	511	keV,	as	well	 as	 investigating	 the	 effects	 of	 any	 change	 in	 LAC	 on	 the	 quantification	 of	 PET	image-based	activity	concentration	using	3	different	attenuation	correction	methods.				
  
Material	and	Methods	
	
Solution	preparation		In	 order	 to	 simulate	 a	 ‘worst-case	 scenario’	 of	 the	 maximum	 possible	 GBCA	concentration	 in	 the	 left	ventricle	of	 the	heart	during	clinical	 imaging,	an	assumption	was	made	 that	 an	 entire	 bolus	 of	GBCA	 can	be	present	 in	 the	 left	 ventricle.	 Thus	we	assumed	a	maximum	bolus	volume	of	20	ml	being	diluted	 in	an	average	end	diastolic	left	 ventricle	 volume	 (EDV)	 of	 150	 ml	 (142	 ±	 21	 ml	 is	 a	 reported	 EDV	 range	 (7)).	Assuming	 20	 ml	 of	 0.5	 mmol/ml	 solution	 GBCA	 in	 left	 ventricle,	 the	 molar	concentration	of	GBCA	(from	Table	1)	can	reach	a	potential	maximum	of	approximately	70	mM.	After	ejection	of	the	GBCA	from	the	heart,	the	concentration	in	the	left	ventricle	then	quickly	reduces	(over	approximately	30-50	seconds)	as	it	distributes	into	a	larger	blood	volume.	Thus	our	 static	 experiments	 aimed	 to	 cover	 the	minimum	 to	potential	maximum	range	of	GBCA	concentrations	in	the	left	ventricle	during	the	times	that	both	MR	and	PET	arterial	input	functions	are	measured	on	resulting	reconstructed	images.		A	thin	plastic	bottle	(max	volume	=	160	ml,	d=5cm,	h=8.5cm)	was	filled	with	120	ml	of	distilled	water	together	with	40	MBq	of	[18F]-NaF	in	0.2	ml	(as	measured	in	a	standard	dose	calibrator	with	±5%	accuracy)	in	order	to	provide	measurements	of	PET	activity	concentration.		
We	then	added	DOTAREM	0.5	mmol/l	(8)	-a	GBCA	utilized	throughout	our	hospital-	in	incremental	3	mM	steps	until	a	30	mM	solution	was	reached	(10	concentration	steps).	After	reaching	30	mM,	4	mM	steps	(10	steps	 in	 total)	were	added	to	make	a	solution	with	 final	 concentration	 of	 66	 mM.	 At	 each	 concentration	 step,	 the	 solution	 was	scanned	on	a	CT	scanner	followed	by	a	PET-MRI	scanner.	
  
Scanning	CT	 images	 were	 acquired	 only	 for	 calculation	 of	 the	 LAC	 of	 the	 solution	 on	 a	 GE	Discovery	710	PET-CT	scanner	(140	kV,	20mA,	0.5s	rotation,	40	mm	collimation).	No	PET	scanning	was	performed	on	 the	PET-CT	scanner.	PET-MR	scans	were	performed	on	 a	 simultaneous	 whole-body	 PET-MR	 scanner	 (Siemens	 Biograph	 mMR,	 Siemens	Healthcare,	Erlangen,	Germany)	located	next	door	to	the	PET-CT	scanner.	Each	PET-MR	scan	lasted	3	minutes	and	all	PET	data	was	decay	corrected	to	a	common	timepoint.			By	default	during	PET	scanning,	an	MR-based	attenuation	correction	(MRAC)	sequence	was	 performed	 with	 each	 PET-MR	 scan	 at	 each	 GBCA	 concentration	 step.	 This	 was	generated	using	 the	 standard	dual-point	VIBE	T1-weighted	Dixon	 sequence	provided	by	the	manufacturer	on	the	scanner.			
	
Mixture	rule	for	calculation	of	LAC		In	order	to	understand	how	the	introduction	of	GBCA	can	affect	the	 image-based	PET	activity	concentration	during	simultaneous	PET-MR,	 it	 is	 important	to	understand	the	attenuation	 properties	 of	 the	 different	 components	 at	 511	 keV.	 Data	 for	 the	 mass	attenuation	coefficient	 (MAC	–	characterizes	how	easily	 the	material	 is	penetrated	by	gamma	radiation)	of	Gd	and	water	are	shown	in	Fig.	1	(9).	At	150	kV	(close	to	the	CT	energy	of	140	kV),	markedly	different	MACs	of	1.1	cm2/g	and	0.1505	cm2/g	for	Gd	and	water	respectively	can	be	observed.	However	at	500	kV	(close	to	PET	gamma	energy	of	511	 keV),	 these	 MAC	 are	 more	 similar,	 0.1139	 cm2/g	 and	 0.0969	 cm2/g	 for	 Gd	 and	water	respectively.	The	measured	LAC	of	other	tissues	of	the	body	at	511	keV	are	also	similar	at	this	energy	(9)	(skeletal	muscle	=0.1010	cm-1	(10),	adipose	tissue	=0.09	cm-1	
(11)	and	whole	blood	=	0.0905	cm-1	(11)).		
  
	The	 MAC	 of	 a	 homogenously	 mixed	 solution	 can	 be	 approximated	 by	 Hubbell’s	weighted	 average	 mixture	 rule	 for	 homogenous	 solutions	 with	 photon	 energies	 >10	keV	(9):															 							𝜇!(!"#$) = 𝜇!(!)! 𝑤(!)																																								(1)	where	μM(soln)	represents	the	MAC	of	the	total	solution	and	μM(i)	and	w(i)	represent	the	MAC	(cm2/g)	and	fractional	weight	of	the	ith	components	of	the	mixture.	Given	that	the	solution	of	GBCA	can	be	approximated	to	a	mixture	of	gadolinium	(Gd)	and	water	(wa),	this	can	be	written	as:		 	𝜇!(!"#$) = 𝜇!(!")𝑤(!") + 𝜇!(!")𝑤(!")	 	 													 (2)	Thus	assuming	the	measured	values	of	MAC	at	500	keV	are	representative	of	those	at	511	 keV,	 in	 order	 to	 determine	 the	MAC,	 and	 hence	 the	 LAC	 (LAC	 =	MAC	 *	 solution	density),	the	total	mass	of	solution	and	fractional	weights	of	water	and	gadolinium	are	required.	 Given	 that	 μM(wa)	 and	 μM(Gd)	 	 at	 511	 keV	 are	 0.9687	 and	 0.1139	 cm2/g	respectively	(from	Fig	1),	the	final	mixture	will	have	μM(soln)	confined	to	μM(Gd)>μM(soln)> 
μM(wa).			
Image	reconstruction	and	analysis		
Investigation	of	LAC	All	CT	images	were	reconstructed	on	the	PET-CT	scanner	using	a	filtered	back-projection	(FBP)	algorithm	as	standard	on	the	scanner	software.	Transformation	from	Hounsfield	 Units	 (HU)	 to	 LAC	 at	 511	 keV	 was	 performed	 offline	 using	 a	 bi-linear	calibration	curve	(140	kVp)	as	implemented	on	the	PET-CT	scanner.	LAC	values	applied	to	 the	 images	 by	 the	 MRAC	 segmentation	 procedure	 (each	 voxel	 in	 the	 image	
  
represents	LAC	x	10,000)	were	obtained	from	the	MR	attenuation	map	by	viewing	the	images	 on	 the	 scanner	 software	 and	 noting	 down	 the	 common	 LAC	 value	 applied	 to	each	voxel	of	the	solution	in	the	phantom.		
	
PET	quantification	In	 order	 to	 quantify	 any	 effect	 a	 change	 in	 GBCA	 concentration	 (and	 hence	 a	change	in	LAC)	of	the	solution	may	have	on	final	PET	image	data,	attenuation	correction	of	 the	PET	data	 is	 required.	All	PET	data	were	reconstructed	on	 the	PET-MR	scanner	using	standard	clinical	reconstruction	parameters	(OSEM,	3	iterations	21	subsets,	344	image	 matrix).	 PET	 data	 was	 not	 reconstructed	 using	 the	 default	 MRAC	 algorithm	provided	 on	 the	 scanner	 of	 each	 GBCA	 step,	 instead	 PET	 emission	 sinograms	 were	attenuation	corrected	with	three	different	methods:		1. AC1	 -	 Each	 PET	 image	 corrected	 by	 its	 corresponding	 CT	 derived	 attenuation	map.	 Each	 CT	 derived	 attenuation	 map	 was	 registered	 to	 the	 MR-derived	attenuation	map	using	 a	 rigid	 registration	 through	Niftyreg	 software	 (12)	 and	subsequently	uploaded	to	the	PET-MR	scanner	for	attenuation	correction	of	PET	data.	2. AC2	–	A	CT	derived	attenuation	map	with	LAC	values	resulting	from	a	CT	scan	of	the	 phantom	 at	 0	mM	 (i.e.	 no	 GBCA	 present).	 The	 dataset	was	 registered	 and	uploaded	to	the	scanner	as	described	for	method	AC1.		3. AC3	 –	 A	 manually	 generated	 attenuation	 map	 whereby	 all	 CT	 voxels	 in	 the	phantom	were	manually	set	to	0.1	cm-1.		Method	AC1	provides	a	standard	method	for	attenuation	correction,	given	that	the	LAC	calculated	from	the	bi-linear	scaling	of	CT	data	from	each	GBCA	step	is	being	
  
used	to	correct	its	corresponding	PET	scan.	Method	AC2	is	employed	as	is	common	in	a	clinical	 scenario,	where	a	 single	MR-attenuation	map	acquired	before	 the	 injection	of	PET	 radiotracer	 and	 GBCA	 is	 used	 to	 attenuation	 correct	 all	 dynamic	 PET	 frames.	Method	AC3	represents	a	scenario	of	using	a	single	“soft	tissue”	LAC	value	as	would	be	assigned	by	the	MRAC	segmentation	algorithm	on	clinical	scanning.		All	PET	and	CT	image	analyses	were	performed	in	OsiriX	[Pixmeo	SARL,	Geneva,	Switzerland].	A	rectangular	volume	of	interest	(VOI)	corresponding	to	a	central	portion	of	 the	 solution	was	drawn	on	 the	phantom	 (volume	=	75	 cm3)	 at	 each	 concentration	step.	 The	 average	 HU,	 image-based	 PET	 activity	 concentration	 (kBq/ml)	 and	 VOI	standard	deviations	were	obtained	from	the	relevant	slices	(28	CT	slices,	50	PET	slices).	Resulting	 PET	 data	 were	 decay	 corrected	 to	 a	 common	 timepoint,	 and	 were	 also	corrected	 for	 the	 increasing	 volume	 of	 the	 solution	 in	 order	 to	 visualize	 differences	from	 the	 true	 activity	 concentration	 and	 from	 the	 LAC	 of	 the	 solution	 at	 0	 mM	concentration.		
Results	
Investigation	of	LAC		Fig	2	shows	a	comparison	of	LAC	with	increasing	GBCA	concentration	for	the	mixture	rule	(Eqn	2)	and	resulting	LAC	from	CT	scanning	(bi-linear	conversion	from	HU	to	LAC	at	 511	 keV).	 LACs	 as	 generated	 by	 the	 MRAC	 segmentation	 are	 also	 shown	 for	comparison	 only.	 LACs	 of	 the	 solution	 generated	 from	CT	 imaging	 show	 a	maximum	increase	 of	 approximately	 2%	over	 the	 range	 of	 0	mM	and	 66	mM,	which	 correlates	well	with	the	increase	predicted	from	the	mixture	model	as	described	above.			
Effect	on	PET	Quantification	
  
Fig	3	shows	the	effect	of	the	different	attenuation	correction	strategies	(AC1,	AC2	and	AC3)	on	the	quantification	of	PET	data.	The	true	activity	concentration	in	the	phantom	was	calculated	at	each	time	point	from	the	knowledge	of	the	original	activity	placed	in	the	 phantom,	 compensated	 for	 decay	 and	 also	 the	 increasing	 volume	 at	 each	concentration	 step.	 The	 image-based	 activity	 concentration	 is	 comparable	 across	 all	three	attenuation	correction	methods,	and	no	trends	are	visible	with	increasing	GBCA.	Errorbars	 in	 the	 activity	 concentration	 represent	 the	 mean	 kBq/ml	 ±	 one	 standard	deviation	of	 the	mean,	 in	 order	 to	 indicate	 the	 level	 of	 noise	present	 in	 the	 resulting	images.	It	should	be	noted	that	in	dynamic	imaging	a	higher	level	of	noise	is	likely	to	be	obtained	due	to	short	frame	times	(potentially	as	short	as	5-10	seconds	depending	on	the	imaging	protocol),	and	low	noise	here	indicates	good	count	statistics	only.		
	
Discussion		Our	primary	goal	in	these	experiments	was	to	evaluate	the	change	in	LAC	of	a	mixture	of	PET	radiotracer	and	increasing	concentrations	of	GBCA,	and	also	to	investigate	if	this	change	produces	a	measurable	effect	on	the	image-based	PET	activity	concentration.			
Investigation	of	LAC		As	proposed	by	Fig.	1,	the	effect	of	increasing	concentrations	of	GBCA	on	quantification	of	 image-based	 PET	 activity	 concentration	 should	 be	 limited	 to	 a	 very	 small	 range	between	the	MAC	of	water	and	gadolinium	at	a	photon	energy	of	511	keV.			As	 detailed	 in	 Fig.	 2,	 LAC	 comparisons	 via	 bi-linear	 CT	 closely	match	 the	 LAC	 values	resulting	from	the	mixture	rule	calculations	(Eqn	2)	with	an	increase	of	approximately	2%	 in	 LAC	 over	 the	 increasing	 GBCA	 range	 of	 0	 mM	 to	 66	mM.	 This	 details	 that	 in	
  
general,	the	mixture	model	can	be	utilised	to	predict	the	LAC	of	a	solution	of	water	and	GBCA	 for	 phantom	 studies.	 Erroneous	 values	 of	 LAC	 derived	 from	 the	 MRAC	segmentation	procedure	are	shown	 in	Fig.	2	 for	comparison	to	 the	data	derived	 from	the	mixture	model	and	from	CT	imaging	only.	Studies	have	shown	in	vivo	the	T1	and	T2	shortening	effects	due	to	the	use	of	GBCA	in	contrast	enhancement	studies,	with	a	range	from	 30%	 to	 68%	 shortening	 of	 T1	 post	 administration	 of	 0.1mmol/kg	 body	weight	
(13).	The	effect	of	GBCA	on	clinically	derived	MR	attenuation	maps	has	recently	been	demonstrated	 (14),	 showing	 an	 overestimation	 of	 image-based	 activity	 concentration	due	 to	an	assignment	of	part	of	 the	 lung	 tissue	 to	soft	 tissue	by	 the	MRAC	due	 to	 the	presence	of	GBCA.	This	produced	a	measurable	effect	due	to	the	large	difference	in	LAC	between	lung	and	soft	tissue.	In	a	simultaneous	PET-MRI	clinical	cardiac	acquisition	the	AC	 procedure	 would	 be	 free	 from	 the	 influences	 of	 GBCA	 if	 the	 MRAC	 scan	 were	performed	 before	 the	 administration	 of	 GBCA.	 However,	 if	 additional	 MRAC	 are	performed	after	GBCA	administration,	effects	of	GBCA	on	 the	segmentation	algorithm	have	to	be	taken	into	account.				
Effects	on	PET	Quantification	Fig.	3	details	the	accuracy	of	the	correction	strategies	(AC1,	AC2	and	AC3)	to	the	true	activity	 concentration	of	each	solution.	We	did	not	employ	attenuation	correction	via	the	default	MRAC	procedure	due	to	the	inaccuracies	of	the	MRAC	in	defining	LAC	of	the	solution	as	detailed	above.	All	 three	AC	methodologies	were	within	5%	of	the	ground	truth	activity	 concentration,	 although	AC3	gave	 the	most	 accurate	mean	 image-based	activity	 concentration	 over	 all	 solutions	 to	 the	 true	 value.	 Values	 consistently	 lower	than	 the	 true	 activity	 concentration	 were	 a	 maximum	 of	 2.5%,	 and	 are	 likely	 to	originate	 from	 the	 calibration	 factor	 between	 the	 dose	 calibrator	 and	 PET	 scanner,	
  
although	this	value	is	well	within	the	locally	set	tolerance	of	5%.	A	mean	difference	of	1.5%	was	observed	between	PET	data	corrected	by	methods	AC1	and	AC2.	Method	AC3	represents	the	closest	to	a	clinical	approximation,	as	this	is	the	determined	LAC	of	the	‘soft	tissue’	class	from	MRAC	segmentation,	and	would	be	applied	to	the	heart	and	its	contents	 in	 a	 clinical	 cardiac	 PET-MR	 acquisition.	 Although	 an	 LAC	 of	 0.1	 cm-1	 was	manually	applied	to	the	phantom	data	to	simulate	the	value	applied	to	the	heart	by	the	MRAC	segmentation,	method	AC3	is	valid	only	for	this	phantom	setup	as	the	effects	of	segmentation	 and	 LAC	 determination	 of	 structures	 external	 to	 the	 phantom	 (such	 as	non-cardiac	 tissues	 in	 a	 clinical	 scenario)	 were	 not	 investigated	 in	 this	 work.	 It	 is	important	to	note	also	that	the	solution	in	our	study	was	water	mixed	with	tracer	and	GBCA,	rather	than	blood	(MACBLOOD	=	0.0959	cm2/g	at	511	keV),	which	may	produce	a	different	effect	on	LAC	determination	from	the	automatic	segmentation	routine.			Our	 assumption	 of	 all	 of	 the	 GBCA	 pooling	 in	 the	 left	 ventricle	 together	 with	 the	radiotracer	 is	 likely	 to	 be	 an	 overestimation	 of	 the	 true	 scenario.	 In	 practical	circumstances	 the	GBCA	 in	 cardiac	MR	 studies	 is	 injected	 at	 a	 rate	 of	 3	ml/s.	With	 a	standard	 heart	 rate	 of	 60	 bpm,	 GBCA	 would	 be	 cleared	 rapidly	 from	 the	 ventricle,	indicating	that	the	true	GBCA	concentration	during	a	dynamic	acquisition	is	likely	to	be	a	 lot	 lower	 that	66	mM.	However	we	have	addressed	a	broad	concentration	 range	of	GBCA	up	to	this	maximum	point.			Static	 imaging	 in	 order	 to	 investigate	 the	 effects	 of	 GBCA	 on	 image-based	 activity	concentration	 was	 performed	 in	 order	 to	 control	 all	 parameters	 except	 GBCA	concentration,	 rather	 than	 the	 use	 of	 a	 dynamic	 phantom	whereby	 concentrations	 of	both	GBCA	and	PET	radiotracer	are	both	changing	rapidly.	The	use	of	a	dynamic	cardiac	
  
perfusion	 phantom	 for	 investigations	 into	 quantification	 of	 MR	 cardiac	 perfusion	studies	 (15)	 would	 allow	 the	 investigation	 of	 the	 attenuation	 effects	 on	 dynamically	acquired	PET	 and	MR	 input	 functions.	Use	 of	 such	 a	 high	 concentration	 of	GBCA	 (66	mM)	 may	 lead	 to	 effects	 of	 signal	 saturation	 (itself	 potentially	 corrected	 for	 by	adjustment	 of	 the	 magnetization	 flip	 angle	 in	 gradient	 echo	 sequences	 (16))	 in	 the	derivation	of	an	MR	input	function,	the	effects	of	which	could	also	be	investigated	with	a	phantom.	Furthermore,	 the	use	of	an	anthropomorphic	 torso	phantom	with	cardiac	insert	 could	 provide	 a	 more	 realistic	 comparison	 to	 a	 clinical	 scenario	 (i.e.	 such	 as	scattering	 of	 gamma	 ray	 photons).	 This	 would	 have	 required	 regular	 access	 to	 the	cardiac	 chamber	 of	 the	 phantom	which	was	 impractical	with	 the	 amount	 of	 steps	 of	increasing	concentration	used	in	this	study.	Also,	the	study	was	concerned	mainly	with	a	carefully	controlled	study	of	the	quantitative	accuracy	of	PET	when	mixed	in	solution	with	GBCA,	and	thus	a	true	patient	representation	was	not	required.				In	 order	 to	 avoid	 the	 potential	 confounding	 effects	 of	 dead-time	 on	 the	 PET	scanner	when	 all	 of	 the	 radiotracer	 is	 placed	 in	 the	 field	 of	 view	 of	 the	 scanner,	we	utilised	 a	 PET	 activity	 of	 [18F]-NaF	 of	 40	MBq.	 This	 represents	 an	 activity	 far	 lower	than	 that	 usually	 received	 by	 patients	 at	 our	 centre	 undergoing	 [13N]-NH3	 cardiac	imaging.	 The	 effect	 of	 dead-time	 has	 been	 quantified	 on	 previous	 cardiac	 studies	 on	PET-CT	 systems,	 for	 example	 the	 effect	 on	myocardial	 perfusion	 quantification	 (17),	and	also	the	limit	of	dead-time	losses	by	weight-based	activity	administration	protocols	
(18).	Dead-time	effects	have	yet	to	be	investigated	in	cardiac	PET-MR	imaging.	As	this	work	 investigated	 the	 effect	 of	 GBCA	 on	 image-based	measurements	 of	 PET	 activity	concentration,	the	total	activity	in	the	phantom	is	not	an	important	factor,	as	any	GBCA	effect	would	have	the	same	contribution	regardless	of	the	total	activity.	We	also	aimed	
  
to	 reduce	 the	 radiation	 dose	 to	 the	 operator	 as	 much	 as	 possible	 due	 to	 multiple	handling,	filling	and	transport	steps	performed.			
Conclusion	Our	work	employed	a	static	simulation	of	a	bolus	of	gadolinium-based	contrast	agent	(GBCA)	 in	 solution	with	water	 and	 PET	 radiotracer	 in	 a	 simulated	 left	 ventricle.	 Our	results	have	shown	that	when	considering	high	concentrations	of	up	to	66	mM	of	GBCA,	the	 linear	 attenuation	 coefficient	 (LAC)	 of	 the	 mixed	 solution	 increases	 by	approximately	2%	over	the	0-66	mM	range.	The	quantitative	accuracy	of	the	resulting	reconstructed	PET	images	when	attenuation	corrected	by	CT	data,	and	also	a	manually	applied	attenuation	map	is	minimally	affected	by	the	presence	of	the	GBCA.		
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FIGURE	CAPTIONS	
	
Fig.	1.	Mass	attenuation	spectra	of	water	and	gadolinium,	with	a	line	drawn	at	511	keV	
  
showing	the	similar	mass	attenuation	coefficients.	Inset	shows	a	close-up	of	the	values	at	511	keV.	At	500	keV	(the	last	measured	point),	this	difference	in	μM	is	14.95%.	Data	has	been	replotted	from	tabulated	data	originally	published	by	Hubbell	(9).		
	
Fig.	2.	The	LAC	as	determined	by	bi-linear	CT	calculation,	and	the	theoretical	mixture	model.	MRAC	derived	LAC	values	are	shown	for	comparison	only	and	were	not	used	to	correct	PET	data.	CT	and	mixture	model	are	closely	correlated,	showing	an	increase	of	approximately	 2%	 up	 to	 66	mM.	 The	MRAC	 segmentation	 routine	 fails	 to	 determine	accurate	LAC	at	higher	mM	concentrations	due	to	T1	shortening	effects	caused	by	the	presence	of	high	concentrations	of	GBCA.		
  
	
Fig.	3.	Comparison	of	decay	corrected	and	volume	corrected	image-based	PET	activity	concentrations.	PET	data	acquired	on	the	PET-MR	system	were	attenuation	corrected	by	 three	different	methods;	 (top)	AC1	using	 the	CT	scan	 from	each	 increasing	step	 in	GBCA,	(middle)	AC2	by	using	the	first	CT	scan	with	no	GBCA	present,	and	(bottom)	AC3	from	 a	 manually	 generated	 attenuation	 map	 where	 all	 voxels	 have	 LAC=0.1	 cm-1.		Errorbars	represent	1	standard	deviation	of	the	VOI	used	to	calculate	the	mean	of	PET	data.	 No	 trends	 in	 mean	 image-based	 activity	 concentration	 can	 be	 observed	 while	increasing	GBCA	concentration	for	any	of	the	attenuation	correction	methods.		
  
TABLES				 Parent	solution	 Active	component	 Molecular	weight	of	active	component		(g/mol)	
Mass	of	active	component	in	1	ml	of	parent	solution	(mg)	
Mass	of	Gd	in	1	ml	of	parent	(mg)	
DOTAREM®	0.5	mmol/ml	 Gadoteric	acid	 558.64	 279.32	 78.625	Gadovist	®1mmol/ml	 Gadobuterol	 604.71		 604.71	 157.25	Magnevist	®	0.5	mmol	 Gadopentetic	acid	 545.56	 469.01	 78.625	MultiHance®	0.5	mmol	 Gadobenic	acid	 667.72	 529.00	 78.625		
Table	 1.	 The	 composition	 of	 common	MR	 contrast	 agents	 in	 terms	 of	 the	 amount	 of	Gadolinium	 present	 in	 the	 solution	 from	 summary	 of	 product	 characteristics	datasheets.	Added	chelator	may	be	present	around	the	Gd	complex.	The	molar	mass	of	gadolinium	is	157.25	g/mol.		
 		
